19 related articles for article (PubMed ID: 9719457)
1. Rhodamine 123-efflux from hematopoietic subpopulations and leukaemic blast populations marked by PerCP-conjugated monoclonal antibodies.
Beck J; Gekeler V; Ringger M; Handgretinger R; Niethammer D
Cancer Lett; 1996 Feb; 99(2):197-207. PubMed ID: 8616825
[TBL] [Abstract][Full Text] [Related]
2. Modulation of multidrug resistance by BIBW22BS in blasts of de novo or relapsed or persistent acute myeloid leukemia ex vivo.
Schröder J; Esteban M; Müller MR; Kasimir-Bauer S; Bamberger U; Heckel A; Seeber S; Scheulen ME
J Cancer Res Clin Oncol; 1996; 122(5):307-12. PubMed ID: 8609155
[TBL] [Abstract][Full Text] [Related]
3. In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells.
den Ouden D; van den Heuvel M; Schoester M; van Rens G; Sonneveld P
Leukemia; 1996 Dec; 10(12):1930-6. PubMed ID: 8946933
[TBL] [Abstract][Full Text] [Related]
4. Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833.
Robey R; Bakke S; Stein W; Meadows B; Litman T; Patil S; Smith T; Fojo T; Bates S
Blood; 1999 Jan; 93(1):306-14. PubMed ID: 9864175
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometric functional analysis of multidrug resistance by Fluo-3: a comparison with rhodamine-123.
Koizumi S; Konishi M; Ichihara T; Wada H; Matsukawa H; Goi K; Mizutani S
Eur J Cancer; 1995 Sep; 31A(10):1682-8. PubMed ID: 7488425
[TBL] [Abstract][Full Text] [Related]
6. Rhodamine 123 efflux modulation in the presence of low or high serum from CD56+ hematopoietic cells or CD34+ leukemic blasts by B9309-068, a newly designed pyridine derivative.
Beck JF; Buchholz F; Ulrich WR; Boer R; Sanders KH; Niethammer D; Gekeler V
Cancer Lett; 1998 Jul; 129(2):157-63. PubMed ID: 9719457
[TBL] [Abstract][Full Text] [Related]
7. Assays for the analysis of P-glycoprotein in acute myeloid leukemia and CD34 subsets of AML blasts.
Sonneveld P; Wiemer E
Leukemia; 1997 Jul; 11(7):1160-5. PubMed ID: 9205006
[TBL] [Abstract][Full Text] [Related]
8. Development of multidrug-resistance convertors: sense or nonsense?
van Zuylen L; Nooter K; Sparreboom A; Verweij J
Invest New Drugs; 2000 Aug; 18(3):205-20. PubMed ID: 10958589
[TBL] [Abstract][Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
